The effectiveness of intravenous lacosamide therapy in the treatment of epilepsy has been underlined by a new study.Led by University Hospital Schleswig-Holstein, in Germany, the research aimed to evaluate the efficacy and tolerability of intravenous (iv) lacosamide under routine conditions in daily clinical practice.A total of 119 people were recruited to the study, from 16 neurological and neuropaediatric centres in which the treating physicians decided to administer iv lacosamide for any reason. Subjects with any type of seizure or epilepsy syndrome were eligible to be involved.Participants were observed for ten days, with daily documentation of iv lacosamide administration. Data was also collated on the type and frequency of seizures experienced, currently used drugs and doses, and adverse events.The findings, published in the medical journal Seizure, showed that 45 of 64 patients affected by status epilepticus or a series of seizures saw their epileptic activity cease during the observation period.Abnormalities in heart rhythm were found in five subjects prior to the iv infusion and in one subject afterwards, but during the infusion process no such abnormalities were reported. The physicians involved in administering the iv treatment rated the efficacy and tolerability of the drug as being very good or good in 77.6% and 93.1% of patients, respectively.The research concludes: “This large and independent multi-center registry on the use of intravenous lacosamide in clinical practice demonstrates that intravenous lacosamide is well-tolerated and highly efficacious when given in emergency situations, including patients experiencing status epilepticus. It is advisable to perform an electrocardiogram prior to intravenous lacosamide administration.”Click here for more articles about anti-epileptic drugs and pregnancy risks.